DTx for women’s mental health – Woebot and postpartum depression
Pharma Phorum
JANUARY 25, 2023
Digital therapeutics company Woebot Health has announced enrolment of the first patient in a pivotal clinical trial to evaluate the safety and efficacy of WB001, an investigational therapeutic for postpartum depression (PPD), granted Breakthrough Device designation by the US Food and Drug Administration (FDA) in 2021.
Let's personalize your content